Therefore, targeting the expression of FATP5 or the interaction between TEAD4 and YAP1 may represent a promising therapeutic strategy to reduce PCa proliferation and inhibit disease progression. The gene discussed is SLC27A5; the disease is posterior cortical atrophy.